anti-SARS-CoV-2 inactivated convalescent plasma / Shanghai Public Health Clinical Center - LARVOL DELTA

Nirmatrelvir increases blood tacrolimus concentration in COVID-19 patients as determined by UHPLC-MS/MS method. (PubMed, Eur Rev Med Pharmacol Sci) - "We developed a simple quantification method for therapeutic drug monitoring of FK506 in patients with COVID-19 using UHPLC-MS/MS with protein precipitation. We found that NMV increased FK506 blood concentration 10-fold. Therefore, it is necessary to re-consider co-administration of FK506 with NMV."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Transplantation

Acriflavine and proflavine hemisulfate as potential antivirals by targeting M. (PubMed, Bioorg Chem) - "In order to get potential anti-SARS-CoV-2 agents, we established an enzymatic assay using a fluorogenic substrate to screen the inhibitors of M. Fortunately, Acriflavine (ACF) and Proflavine Hemisulfate (PRF) with the same acridine scaffold were picked out for their good inhibitory activity against M with IC of 5.60 ± 0.29 μM and 2.07 ± 0.01 μM, respectively...Both compounds showed nano-molar activities against SARS-CoV-2 virus, which were superior to GC376 for anti-HCoV-43, and equivalent to the standard molecule remdesivir. Our study demonstrated that ACF and PRF were inhibitors of M, and ACF has been previously reported as a PL inhibitor. Taken together, ACF and PRF might be dual-targeted inhibitors to provide protection against infections of coronaviruses."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies. (PubMed, Cell Discov) - "The highly mutated and transmissible Omicron (BA.1) and its more contagious lineage BA.2 have provoked serious concerns over their decreased sensitivity to the current COVID-19 vaccines and evasion from most anti-SARS-CoV-2 neutralizing antibodies (NAbs)...These novel bispecific antibodies are strong candidates for the treatment and prevention of infection with the Omicron, BA.2, VOCs, and other sarbecoviruses. Engineering bispecific antibodies based on non-Omicron NAbs could turn the majority of NAbs into a powerful arsenal to aid the battle against the pandemic."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity. (PubMed, Gut Microbes) - "Similarly, we found that levels of preexisting S2 and P144-specific antibodies correlated positively with RBD binding antibody titers after two doses of inactivated SARS-CoV-2 vaccination in human. Collectively, our study revealed an alternative origin of preexisting S2-targeted antibodies and disclosed a previously neglected aspect of the impact of gut microbiota on host anti-SARS-CoV-2 immunity."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Transplantation • HSPD1

An Open, Prospective Cohort Study of VV116 in Chinese Participants Infected with SARS-CoV-2 Omicron Variants. (PubMed, Emerg Microbes Infect) - P2/3, P3 | "VV116 is an oral drug with robust anti-SARS-CoV-2 efficacy in preclinical studies...A total of 9 adverse events with no serious adverse events were reported in the VV116 group, 7 of which were mild liver function abnormalities, and all of them were resolved without intervention. VV116 is a safe, effective oral antiviral drug, which shows a better performance within the early onset of omicron infection.Trial registration: ClinicalTrials.gov identifier: NCT05242042.Trial registration: ClinicalTrials.gov identifier: NCT05279235.Trial registration: ClinicalTrials.gov identifier: NCT05341609."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Rapid SARS-CoV-2 antigen detection potentiates early diagnosis of COVID-19 disease. (PubMed, Biosci Trends) - "Eighty-five COVID-19 patients were enrolled for detection of SARS-CoV-2 viral antigens, including 57 anti-SARS-CoV-2 antibody negative cases and 28 antibody positive cases. Furthermore, positive antigen detection indicated disease progression, nine cases with positive antigen (9/30, 30.0%), in contrast to two cases (2/27, 7.40%) (p = 0.0444) with negative antigen, which progressed into severe disease. Thus, the viral antigens were persistent in early stages of infection when virus was in highly replicating status, and viral antigen detection promises to rapidly screen positive patients in the early stage of SARS-CoV-2 infection."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases